Annual, English, IR, Listing Regulation, News, Regulatory, Report

Acarix AB’s Annual Report 2023

23 Apr

Acarix, a leader in advanced acoustic-based cardiac diagnostics, today announces that the Annual Report for 2023 is available as a pdf on the company’s website.

https://www.acarix.com/for-investors/financial-reports-and-calendar

The Annual Report is available in Swedish and English.

For more information contact:
Jennifer Anderson, Head of Marketing & Communications, phone +1 720 471 4625, email jennifer.anderson@acarix.com 

About Acarix

Acarix is a Swedish medical device company that innovates solutions for rapid rule out of coronary artery disease (CAD) at point of care. The CE-approved and FDA DeNovo-cleared Acarix CADScor System is intended for patients experiencing chest pain with suspected CAD and designed to help reduce millions of unnecessary, invasive, and costly diagnostic procedures. The CADScor System has been used on more than 29,000 patients. Acarix recommends CADScor System as a first-line diagnostic aid that uses highly sensitive acoustics and advanced computational processing to analyze coronary blood flow to rule out significant coronary artery disease (CAD), with at least 96% certainty at point of care. Acarix is listed on the Nasdaq First North Premier Growth Market in Stockholm (ticker: ACARIX). Carnegie Investment Bank is the Certified Advisor of Acarix. For more information, please visit www.acarix.com

Attachments
Acarix ENG AnnualReport 2023 FINAL

Acarix ENG AnnualReport 2023 FINAL
Newer Acarix receives order from the first freestanding Emergency Room in the US
Back to list
Older KALLELSE TILL ÅRSSTÄMMA I ACARIX AB